Early benefits of empagliflozin in patients with type 2 diabetes with heart failure are not offset by increased adverse events: results from the EMPA-REG OUTCOME trial
1 September 2019 (14:00 - 18:00)
Organised by:
Abstract
About the speaker
University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
9 More presentations in this session
Access the full session
The Event
ESC Congress 2019
1 September 2019
14:00 CET
You may be interested in
Congress Presentation
